Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tremelimumab - AstraZeneca

Drug Profile

Tremelimumab - AstraZeneca

Alternative Names: Anti CTLA 4 monoclonal antibody-Pfizer; Anti-CTLA4 Human Monoclonal Antibody CP-675,206; CP-675; CP-675206; Human IgG2 mAb tremelimumab - AstraZeneca; Ticilimumab

Latest Information Update: 16 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer AIO Studien gGmbH; Amgen; ARCAGY/GINECO Group; AstraZeneca; Azienda Ospedaliera Universitaria Senese; Canadian Cancer Trials Group; Charite - Universitatsmedizin Berlin; Dana-Farber Cancer Institute; Fondazione IRCCS Istituto Nazionale dei Tumori; Grupo Espanol de Tumores Neuroendocrinos; Hoosier Cancer Research Network; Immunocore; Institute for Clinical Cancer Research IKF GmbH at Krankenhaus Nordwest; Institute Gustave-Roussy; Kyoto Breast Cancer Research Network; M. D. Anderson Cancer Center; MedImmune; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Northwestern University; Pfizer; Seoul National University Hospital; UNICANCER; University College London; University of Maryland Greenbaum Cancer Center; VU University Medical Center; Yonsei University College of Medicine
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bladder cancer; Head and neck cancer; Liver cancer; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Urogenital cancer
  • Phase II Biliary cancer; Breast cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; Germ cell and embryonal neoplasms; Glioblastoma; Lung cancer; Neuroendocrine tumours; Oesophageal cancer; Oropharyngeal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Sarcoma; Soft tissue sarcoma; Thyroid cancer
  • Phase I/II Haematological malignancies; Malignant melanoma
  • No development reported Diffuse large B cell lymphoma; Gynaecological cancer; Myelodysplastic syndromes; Vulvovaginal cancer

Most Recent Events

  • 09 Sep 2021 Updated efficacy and adverse events data from phase III POSEIDON trial in Non-small cell lung cancer released by AstraZeneca
  • 30 Aug 2021 University of Cincinnati plans a phase II trial for Liver cancer (Combination therapy, First-line therapy) (IV) in October 2021 (NCT05027425)
  • 28 Aug 2021 No recent reports of development identified for phase-I development in Cervical-cancer(Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top